Figure 2 | Scientific Reports

Figure 2

From: Involvement of endothelins in neuroprotection of valosin-containing protein modulators against retinal ganglion cell damage

Figure 2

mRNA expressions of endothelin-1 (Edn1), endothelin receptor type A (Ednra) and endothelin receptor type B (Ednrb) in the mouse retina and primary retinal ganglion cells (RGCs). (a–c) Relative mRNA expression in neural retina. Neural retina of non-treated wild-type mice (W, n = 7) and NMDA-injected (C, n = 8), NMDA-injected-KUS121-treated (K121, n = 8) and NMDA-injected-KUS187-treated (K187, n = 8) mice were analyzed. The relative expression levels of Edn1 (a), Ednrb (b) and Ednra (c) mRNA were analyzed using qRT-PCR. The ratios of mRNA expression of each gene to that of glyceraldehyde-3-phosphate dehydrogenase were calculated. *p < 0.05 and **p < 0.01, vs. W, Tukey’s honestly significant difference (HSD). NS no significant difference compared with W, Tukey’s HSD. (d–f) Relative mRNA expression in primary RGCs. Primary RGCs isolated from 3-day-old rats by two-step immunopanning were cultured with or without KUS121 (50 µM) for 2 h and then with or without KUS121 and with or without NMDA (500 µM) for another 4 h. The relative expression levels of Edn1 (d), Ednrb (e) and Ednra (f) mRNA were analyzed using qRT-PCR. (-): without KUS121 without NMDA n = 3, C: with NMDA without KUS121, n = 3, K121: with NMDA with KUS121, n = 3, respectively. The ratios of mRNA expression of each gene to that of glyceraldehyde-3-phosphate dehydrogenase were calculated. **p < 0.01, control vs. KUS121, NS no significant difference compared with (-), Tukey’s HSD.

Back to article page